Trials / Withdrawn
WithdrawnNCT02176577
Study to Determine the Pharmacokinetics of Product 0405
An Open-Label, Multi-Center Study to Determine the Pharmacokinetics of Product 0405 in the Treatment of Atopic Dermatitis in Adolescent Subjects
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Fougera Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 3 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the Pharmacokinetics of Product 0405 in the Treatment of Atopic Dermatitis in Adolescent Subjects.
Detailed description
Treament medication will be administered topically twice daily for 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Product 0405 | Product 0405 will be administered topically, twice daily for 28 days. |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2014-06-27
- Last updated
- 2014-06-27
Source: ClinicalTrials.gov record NCT02176577. Inclusion in this directory is not an endorsement.